E-LIB Suche - Ergebnisse für: Baroncini, Damiano

1

Towards a validated definition of the clinical transition t..:

Iaffaldano, Pietro ; Lucisano, Giuseppe ; Guerra, Tommaso...
Multiple Sclerosis Journal. 28 (2022) 14 - p. 2243-2252 , 2022

Link: https://doi.org/10.1177/..

2

Long-term follow-up (up to 11 years) of an Italian pediatri..:

Baroncini, Damiano ; Ghezzi, Angelo ; Guaschino, Clara...
Neurological Sciences. 43 (2022) 11 - p. 6415-6423 , 2022

Link: https://doi.org/10.1007/..

3

Switch from sequestering to anti-CD20 depleting treatment: ..:

Signoriello, Elisabetta ; Lus, Giacomo ; Bonavita, Simona...
Multiple Sclerosis Journal. 28 (2021) 1 - p. 93-101 , 2021

Link: https://doi.org/10.1177/..

4

MRI activity and extended interval of Natalizumab dosing re..:

De Mercanti, Stefania Federica ; Signori, Alessio ; Cordioli, Cinzia...
Journal of the Neurological Sciences. 424 (2021) - p. 117385 , 2021

Link: https://doi.org/10.1016/..

5

Etiological research in pediatric multiple sclerosis: A too..:

Pilotto, Silvy ; Gencarelli, Jessica ; Bova, Stefania Maria...
Journal of the Neurological Sciences. 429 (2021) - p. 118133 , 2021

Link: https://doi.org/10.1016/..

6

Etiological research in pediatric multiple sclerosis: A too..:

Pilotto, Silvy ; Gencarelli, Jessica ; Bova, Stefania...
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 7 (2021) 4 - p. 205521732110590 , 2021

Link: https://doi.org/10.1177/..

7

A real‐world study of alemtuzumab in a cohort of Italian pa..:

Russo, Cinzia Valeria ; Saccà, Francesco ; Frau, Jessica...
European Journal of Neurology. 29 (2021) 1 - p. 257-266 , 2021

Link: https://doi.org/10.1111/..

8

First therapy choice in newly diagnosed Multiple Sclerosis ..:

Maniscalco, Giorgia T. ; Saccà, Francesco ; Lanzillo, Roberta...
Multiple Sclerosis and Related Disorders. 42 (2020) - p. 102059 , 2020

Link: https://doi.org/10.1016/..

9

Long-term remission of tumefactive relapsing multiple scler..:

Baroncini, Damiano ; Annovazzi, P. ; Guaschino, C....
Multiple Sclerosis and Related Disorders. 41 (2020) - p. 102061 , 2020

Link: https://doi.org/10.1016/..

10

Extending the Interval of Natalizumab Dosing: Is Efficacy P..:

Clerico, Marinella ; De Mercanti, Stefania Federica ; Signori, Alessio...
Neurotherapeutics. 17 (2020) 1 - p. 200-207 , 2020

Link: https://doi.org/10.1007/..

11

Changes in Management of Pediatric-onset Multiple Sclerosis..:

Baroncini, Damiano ; Iaffaldano, Pietro ; Simone, Marta...
Neurology. 94 (2020) 15_supplement - p. , 2020

Link: https://doi.org/10.1212/..

12

Cell-based assays for the detection of MOG antibodies: a co..:

Gastaldi, Matteo ; Scaranzin, Silvia ; Jarius, Sven...
Journal of Neurology. 267 (2020) 12 - p. 3555-3564 , 2020

Link: https://doi.org/10.1007/..

13

Mild COVID‐19 infection in a group of teriflunomide‐treated..:

Mantero, Vittorio ; Baroncini, Damiano ; Balgera, Roberto...
Journal of Neurology. 268 (2020) 6 - p. 2029-2030 , 2020

Link: https://doi.org/10.1007/..

14

Outcomes after fingolimod to alemtuzumab treatment shift in..:

the i-MuST study group ; Frau, Jessica ; Saccà, Francesco...
Journal of Neurology. 266 (2019) 10 - p. 2440-2446 , 2019

Link: https://doi.org/10.1007/..

15

Clinical trials of disease-modifying agents in pediatric MS..:

Waubant, Emmanuelle ; Banwell, Brenda ; Wassmer, Evangeline...
Neurology. 92 (2019) 22 - p. , 2019

Link: https://doi.org/10.1212/..